R
Rajendra Prasad
Researcher at University of Delhi
Publications - 44
Citations - 456
Rajendra Prasad is an academic researcher from University of Delhi. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 12, co-authored 43 publications receiving 360 citations. Previous affiliations of Rajendra Prasad include Risk and Insurance Management Society & King George's Medical University.
Papers
More filters
Journal ArticleDOI
Comparative Evaluation of Several Gene Targets for Designing a Multiplex-PCR for an Early Diagnosis of Extrapulmonary Tuberculosis
Ankush Raj,Netrapal Singh,Krishna B. Gupta,Dhruva Chaudhary,Aparna Yadav,Anil Chaudhary,Kshitij Agarwal,Mandira Varma-Basil,Rajendra Prasad,Gopal K. Khuller,Promod K. Mehta +10 more
TL;DR: The authors' M-PCR assay demonstrated a high sensitivity of 96% in confirmed EPTB cases and 88.75% in clinically suspected E PTB cases with a high specificity of 100%, taking clinical diagnosis as the gold standard.
Journal ArticleDOI
Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management
TL;DR: The TB control programmes need to prioritize on policies focusing on the effective as well as rational use of first-line drugs in every newly diagnosed drug susceptible TB patients so as to prevent the emergence of drug resistance.
Journal ArticleDOI
Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives.
TL;DR: Early and rapid diagnosis with genotypic tests, prompt treatment with appropriate regimens based on drug-susceptibility testing, preference for shorter regimens fortified with newer drugs, a patient-centric approach, and strong infection-control measures are all essential components in the management of M/XDR-TB in people living with HIV.
Journal ArticleDOI
Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis
TL;DR: Adverse drug reactions to first-line anti-tuberculosis drugs are common and may cause associated morbidity and even mortality if not recognized early, and appropriate management of these adverse effects might determine adherence and treatment success.
Journal ArticleDOI
Isoniazid- and ethambutol-induced psychosis.
TL;DR: A case of 28-year-old male who developed psychotic symptoms on start of EMB initially and later on INH also and was prescribed rifampicin, pyrazinamide, and ofloxacin and had no further psychotic symptoms.